Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022, (Özet Bildiri)
- Yayın Türü: Bildiri / Özet Bildiri
- Basıldığı Ülke: ELECTR NETWORK
- Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet